Gazzard Gus

Realini Tony, Balasubramani G K, Kenkre Tanya, Wolsk Jenny, Kass Michael A, Gazzard Gus et al.

The COAST trial compares standard versus low-energy SLT for new glaucoma/OHT. The abstract details the study design and baseline patient characteristics, showing a representative sample, which will clarify optimal SLT use for long-term glaucoma management.

Ansari Abdus Samad, Jung Minsu, Hamdan Amar, Hayre Amrit, Tan Jeremy, Ansari Daniyal Matin et al.

This study found many statistically significant MIGS trial outcomes are statistically fragile, often due to few events, highlighting the need for cautious interpretation of reported efficacy.

Servillo Andrea, Cutolo Carlo Alberto, Viganò Chiara, Forte Paolo, Manocchio Riccardo, Gazzard Gus et al.

Glaucoma surgical/laser studies show poor adherence (47%) to WGA reporting guidelines, especially for success definitions. This highlights a critical need for updated guidelines and improved reporting to standardize clinical evidence.

Orsine Murta Dias Karla, Yang Elizabeth, Calcagni Antonio, Kawa Jamal Riymon, Gooch James, Shah Diya et al.

Intravitreal HPMC for chronic ocular hypotony improved vision, increased IOP, and restored axial length in most patients, offering a promising treatment for this challenging condition.

Montesano Giovanni, Nathwani Neil, Yu Jonathan, Kong Yu Xiang George, Vingrys Algis, Gazzard Gus et al.

Home visual field tests were more variable than clinic tests, but more frequent home testing could detect glaucoma progression earlier than standard clinic visits.

Montesano Giovanni, Crabb David P, Garway-Heath David F, Wright David M, Konstantakopoulou Evgenia, Nathwani Neil et al.

First-line SLT better preserved visual fields over six years than drops in glaucoma/OHT patients. SLT should be preferred as initial treatment.

Young Su Ling, Gazzard Gus

This review found oral niacin/nicotinamide cause diverse, dose-dependent side effects (e.g., GI upset, flushing), with nicotinamide generally safer. Clinicians should be aware of these AEs, especially for glaucoma patients using these supplements.

Tan Jeremy C K, Kong George, Louis Arnould, Lee Vincent, Clement Colin, Cheng Jason et al.

Different success criteria for glaucoma surgery significantly alter reported failure rates, hindering outcome comparisons. Standardizing reporting is crucial for evaluating surgical effectiveness.

Liu Jocelyn, Kim Iris M, Chen Evan M, Porco Travis C, McLeod Stephen D, Gazzard Gus et al.

US glaucoma specialists increasingly prefer SLT over topical medications for treatment-naive open-angle glaucoma, indicating a shift towards SLT as a primary therapy.

Ramji Saajan, Tan Jeremy C K, Jarrar Zakariya A, Hamid Sana, Gazzard Gus, Ansari Abdus Samad

This meta-analysis found anti-VEGF agents, particularly bevacizumab with mitomycin C, significantly improve trabeculectomy success rates and reduce medication needs in glaucoma patients, offering a valuable surgical adjunct.

Gazzard Gus, Congdon Nathan, Azuara-Blanco Augusto, Blumenthal Eytan Z, Gomelauri Ketevan, Zaliniyan Monika et al.

This study compared direct and conventional SLT for glaucoma/OHT. DSLT wasn't statistically noninferior to SLT at 6 months but effectively lowered IOP for 12 months, offering a viable first-line treatment option.

Lawlor Mitchell, Sun Catherine Q, Gazzard Gus

Konstantakopoulou Evgenia, Gazzard Gus, Garway-Heath David, Adeleke Mariam, Ambler Gareth, Vickerstaff Victoria et al.

Secondary SLT after 3+ years of drops reduced medication for stable glaucoma/OHT patients and lowered IOP for uncontrolled eyes, but didn't eliminate surgery. This supports SLT as a valuable secondary treatment option.

Rabiolo Alessandro, Montesano Giovanni, Gazzard Gus, Caprioli Joseph, De Cillà Stefano

Fahy Eamonn T, Montesano Giovanni, Garg Anurag, Vickerstaff Victoria, Konstantakopoulou Evgenia, Gazzard Gus

This study found that SLT achieved greater IOP lowering than medication at higher baseline pressures, while medication performed better at lower baseline pressures, guiding initial treatment choice.

Konstantakopoulou Evgenia, Varia Jay, Parmar Janisha, Nathwani Neil, Hau Scott, Low Wing Shing et al.

A training program enabled optometrists to safely deliver SLT for glaucoma, demonstrating that non-medical professionals can expand access to this treatment with proper education.

Sacks Zachary, Katz L Jay, Gazzard Gus, Van Tassel Sarah H, Blumenthal Eytan Z, Lerner Fabian S et al.

This paper proposes a fixed low-energy Selective Laser Trabeculoplasty (SLT) for glaucoma. It suggests energy titration is unnecessary, simplifying the procedure, maintaining efficacy, and potentially increasing SLT accessibility for patients.

Jayaram Hari, Kolko Miriam, Friedman David S, Gazzard Gus

Glaucoma causes irreversible vision loss, primarily managed by lowering intraocular pressure. While effective, challenges include late diagnosis and limited evidence for many new treatments, highlighting the need for future neuroprotective and personalized therapies.

Huang Marshall J, Samuelson Thomas W, De Francesco Ticiana, Levin Ariana, Sieck Erin, Gazzard Gus et al.

This case highlights managing severe glaucoma in a second eye after complex, suboptimal surgical outcomes in the first eye, emphasizing individualized treatment and considering novel devices for challenging cases.

Kolko Miriam, Gazzard Gus, Baudouin Christophe, Beier Sofie, Brignole-Baudouin Françoise, Cvenkel Barbara et al.

Montesano Giovanni, Ometto Giovanni, Ahmed Iqbal Ike K, Ramulu Pradeep Y, Chang David F, Crabb David P et al.

Freiberg Josefine, Rovelt Jens, Gazzard Gus, la Cour Morten, Kolko Miriam

This study designs a large Danish optician-based database (FOREVER) to link comprehensive eye exam data with national registries, enabling future research to identify risk factors and associations for various eye and general health conditions.

Safitri Atika, Konstantakopoulou Evgenia, Hu Kuang, Gazzard Gus

Patients with glaucoma value both disease control (vision, independence) and treatment convenience (stable, drop-free). Future patient-reported outcome measures should reflect both aspects for better clinical assessment.

Poostchi Ali, Kastner Alan, Konstantakopoulou Evgenia, Gazzard Gus, Jayaram Hari

This review highlights the urgent need for robust, individualized glaucoma risk stratification models incorporating ocular, systemic, and progression factors to improve patient care and prevent sight loss.

Montesano Giovanni, Ometto Giovanni, Ahmed Iqbal Ike K, Ramulu Pradeep Y, Chang David F, Crabb David P et al.

The HORIZON trial found that glaucoma patients receiving cataract surgery with a Hydrus microstent had significantly slower visual field progression over five years compared to cataract surgery alone.